Fredun Pharma Acquires Pet Wellness Brand Furlicks From USV and Wellbeing Nutrition

MUMBAI — The domestic pet healthcare and nutraceutical sector underwent a major strategic consolidation on Tuesday, September 8, 2026, as Fredun Pharmaceuticals Limited announced a high-profile brand acquisition. According to official corporate disclosures and regulatory filings submitted to stock exchanges, Fredun Pharmaceuticals has formally acquired the pet wellness and functional supplement brand Furlicks from USV Private Limited and Wellbeing Nutrition. The strategic buyout positions the pharmaceutical manufacturer to capture a larger share of the fast-growing pet care market. Company management confirmed that the integration process is underway, with an immediate commercial strategy slated to launch 12 new stock-keeping units (SKUs) in the first phase, followed by an additional 32 SKUs in the second phase.

Expanding Into the Pet Wellness Segment

The acquisition marks a calculated diversification for Fredun Pharmaceuticals, shifting core manufacturing expertise into specialized animal health and preventive care formulations.

• Asset Acquisition: Fredun Pharmaceuticals successfully secured all intellectual property, brand rights, and product lines associated with Furlicks from USV and Wellbeing Nutrition.

• Phased Product Rollout: The commercial strategy entails launching an initial wave of 12 new SKUs, succeeded by a secondary release of 32 specialized products.

• Manufacturing Integration: Production will leverage Fredun’s certified Good Manufacturing Practice (GMP) facilities to scale output for domestic and international markets.

Market Context and Industry Implications

Financial market analysts observe that pet humanization trends and rising disposable incomes across urban centers are driving unprecedented demand for specialized pet supplements, functional treats, and wellness formulations. By acquiring an established digital-first and retail-ready brand like Furlicks, Fredun Pharmaceuticals bypasses the prolonged incubation phase typically required for novel brand launches. Industry participants note that combining USV and Wellbeing Nutrition's innovative formulation concepts with Fredun's robust manufacturing and regulatory compliance framework creates a formidable competitor in the veterinary nutraceutical space.

Official Sources Section

• Corporate filings, acquisition updates, and financial disclosures are submitted to BSE Limited and the National Stock Exchange (NSE).

• Statutory corporate governance and compliance standards are regulated by the Ministry of Corporate Affairs (MCA).

• Capital market rules and listing guidelines are supervised by the Securities and Exchange Board of India (SEBI).

• Brand integration announcements are coordinated through Fredun Pharmaceuticals.

Quote Section

"According to official corporate announcements and regulatory disclosures released by Fredun Pharmaceuticals Limited, the company has acquired the pet wellness brand Furlicks from USV and Wellbeing Nutrition, with plans to launch 44 new SKUs across two phased rollouts."

Why It Matters

For pet owners and veterinary practitioners, the consolidation ensures continued availability and expanded distribution of high-quality wellness formulations. For investors, entering the high-margin pet healthcare segment diversifies revenue streams beyond conventional human pharmaceuticals.

Key Facts at a Glance

• Fredun Pharmaceuticals acquired the pet wellness brand Furlicks.

• The transaction involved buying the brand from USV Private Limited and Wellbeing Nutrition.

• The company plans to launch 12 new SKUs in the first phase and 32 in the second phase.

• Regulatory disclosures were formally submitted to BSE Limited and the National Stock Exchange (NSE).

FAQ Section

What brand did Fredun Pharmaceuticals acquire? Fredun Pharmaceuticals acquired the pet wellness brand Furlicks from USV and Wellbeing Nutrition.

How many new SKUs are planned for release? The company plans to launch 44 new SKUs in total, split across 12 units in the first phase and 32 units in the second phase.

Why is this acquisition significant for the company? It allows Fredun Pharmaceuticals to expand its footprint into the fast-growing pet healthcare and functional nutraceutical market.

Where can official regulatory disclosures of this acquisition be verified? Complete exchange filings and corporate notices are accessible through BSE Limited and the National Stock Exchange (NSE).

Source: BSE Limited, National Stock Exchange (NSE), Ministry of Corporate Affairs (MCA), Securities and Exchange Board of India (SEBI), Fredun Pharmaceuticals Corporate Disclosures